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ABSTRACT
The genome sequence framework provided by
the human genome project allows us to precisely
map human genetic variations in order to study
their association with disease and their direct
effects on gene function. Since the description of
tumor suppressor genes and oncogenes several
decades ago, both germ-line variations and somatic
mutations have been established to be important
in cancer—in terms of risk, oncogenesis, prognosis
and response to therapy. The Cancer Genome Atlas
initiative proposed by the NIH is poised to elucidate
the contribution of somatic mutations to cancer
development and progression through the re-
sequencing of a substantial fraction of the total
collection of human genes—in hundreds of individ-
ual tumors and spanning several tumor types.
We have developed the CancerGenes resource to
simplify the process of gene selection and prioriti-
zation in large collaborative projects. CancerGenes
combines gene lists annotated by experts with
information from key public databases. Each gene
is annotated with gene name(s), functional descrip-
tion, organism, chromosome number, location,
Entrez Gene ID, GO terms, InterPro descriptions,
gene structure, protein length, transcript count,
and experimentally determined transcript control
regions, as well as links to Entrez Gene, COSMIC,
and iHOP gene pages and the UCSC and Ensembl
genome browsers. The user-friendly interface pro-
vides for searching, sorting and intersection of
gene lists. Users may view tabulated results through
a web browser or may dynamically download them
as a spreadsheet table. CancerGenes is available
at http://cbio.mskcc.org/cancergenes.
INTRODUCTION
The completion of a high-accuracy sequence of the human
genome will enable signiﬁcant advances in our understanding
of disease-related genetic variation, both somatic and germ-
line. Researchers are already using the human genome to
study sequence variation in cell populations containing nor-
mal or abnormal DNA. Some of these studies have been
designed to test hypotheses, for example, through linkage
analysis that are concerned with the sequence variations at
one locus or a small group of loci. Other studies have been
designed to catalog variations across a wide selection of
loci or genes, without a particular hypothesis to test, such
as the HapMap project (1). If the study focuses on genotyping
samples using known variations, these genotyping approaches
typically use microarray technology designed to detect hun-
dreds of thousands of single nucleotide polymorphisms
(SNPs), or PCR ampliﬁcation using primers designed to test
for a particular set of SNPs. However, when disease-causing
somatic mutations are unknown, as is the current case for
somatic mutations in nearly all types of cancer, re-sequencing
is the state-of-the-art to discover new variations.
Traditional sequencing technology applied to re-sequencing
a particular genomic region (such as the exons of a gene) may
also be used to detect known mutations. However, because of
its higher cost, re-sequencing is generally performed as a
discovery tool to screen for new genomic sequence variations
and mutations, including base substitutions, insertions and
deletions. In particular, gene re-sequencing efforts have
recently been undertaken largely to catalog synonymous
(not leading to amino acid substitutions) or non-synonymous
(leading to amino acid substitutions) substitutions in genetic
diseases, such as cancer (2–5).
The Cancer Genome Atlas (TCGA) initiative proposed
by the NIH is a large gene re-sequencing effort to take
place over the next decade (NIH Press Release, December
13, 2005; available at http://cancergenome.nih.gov). TCGA
will involve re-sequencing thousands of human genes from
thousands of tumor samples. Without major breakthroughs
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re-sequence all genes and will be limited to particular
tumor types. This large screening effort will naturally be fol-
lowed by other smaller efforts undertaken by individual labs
and small consortia to ﬁll in the gaps, as well as to verify and
validate putative variations on larger sample sizes. A number
of these smaller projects will be targeted at particular genes
and at particular tumors. In all of these projects, large and
small, until sequencing costs drop by several orders of mag-
nitude, funding limits will force decisions about which genes
to re-sequence and in what order they will be examined.
Therefore, selection and prioritization of genes for re-
sequencing is a common ﬁrst step that will be repeated for
each project. With appreciable amounts of sequence and
functional data available in public databases, and without
tools to navigate these data, the gene selection process can
become a painstaking task. The CancerGenes resource will
keep up with the results produced by TCGA by utilizing
the Catalogue of Somatic Mutations in Cancer (COSMIC)
curated resource (6).
Our goal in creating the CancerGenes resource is to simplify
the gene selection process commonly encountered in re-
sequencing projects, and made difﬁcult in large,
geographically dispersed, collaborative groups. Our objective
is to provide a resource that supports gene list storage, queries
and comparisons. For example, a user of this resource could
generate a superset of cancer-related genes listed in Hahn
and Weinberg (7) and Vogelstein and Kinzler (8) by unioning
these gene list sources, ﬁlter this list for tyrosine kinases and
then intersect it with the user’s own gene list. Because of
our interests, we have initially focused on cancer genome re-
sequencing projects, such as TCGA. A key requirement for
rational, high quality gene selection and prioritization is
aggregation of up-to-date gene-centric information, addition
of information by domain experts and summarization. There-
fore, we automated the data aggregation process, provided a
mechanism to add information from domain experts, such as
researchers with intimate knowledge of the importance of par-
ticular gene sets in certain disease processes, and wrote soft-
ware to provide convenient web access to frequently updated
information. In addition, since lists of genes are a common
end-point of many high-throughput studies, such as gene
expression proﬁling using microarrays, we believe this
resource will be a useful adjunct to a wide range of cancer-
relevant studies outside the scope of gene re-sequencing.
MATERIALS AND METHODS
CancerGenes pulls in gene-centric data from four main
sources: NCBI Entrez Gene (9), Ensembl BioMart (10),
supplementary data on active promoter regions from Kim
et al. (11) and the Sanger Institute COSMIC (Table 1) (6).
We use the term ‘gene-centric’ to describe data and resources
whose organizing principle is the gene—i.e. the seminal data
object is based upon the concept of the gene and their func-
tionalities are based on this concept. In contrast, though it
includes gene-centric data, the organizing principle of
CancerGenes is based on list of genes and the list comparison
operations.
Our process uses all active human gene records in Entrez
Gene as the seed data source, and then adds data from the
three other sources. Literature source and annotation gene
lists are then created from various literature and database
sources and queries. These lists are functionally equivalent
to database indices. Details of the current aggregation process
are given below.
Retrieving all human genes from NCBI Entrez Gene
The NCBI Entrez eUtilities (eSearch, eFetch) provide a
means to automate the initial retrieval and future updates of
the gene records in the CancerGenes database (9). We
retrieve gene report records by a single Entrez eSearch
request, which returns numeric Entrez Gene identiﬁers,
followed by a batched eFetch request, which given a list
of Entrez Gene ids, returns data-containing gene records.
We then parse out the following information from ASN.1
formatted records: Entrez Gene ID, gene name, description,
aliases, organism, chromosome number, location, GO terms,
gene size, mRNA length, mRNA exon count, peptide length,
peptide exon count and transcript count. If more than one
protein isoform is reported for a single gene, we use the
information pertaining to the longest. If there are two or
more protein isoforms of the same length, we use the tran-
script information for the longest mRNA. The data are then
loaded into our MySQL database (see below).
BioMart queries for Ensembl gene structure and
InterPro domain data
We retrieve the following gene structure data from the
BioMart/EnsMart system (Table 2): coding DNA sequence
(CDS) length, protein length and transcript count (10). We
handle multiple isoforms as we do with Entrez Gene data
(see above).
InterPro is a database of protein families, domains and
functional sites (12). We retrieve InterPro descriptions from
BioMart in a separate query (Table 3) for insertion into the
MySQL database.
Active human promoter sites
In 2005, Kim et al. (11) generated high-throughput experi-
mental ChIP-on chip data using antibodies against the
Table 1. CancerGenes data sources
Data source Data type URL Number of genes
NCBI Entrez Gene Names, aliases, GO, gene structure http://www.Ncbi.nih.gov/entrez/query.fcgi?db¼gene 39 250
Ensembl BioMart Gene structures, protein domains http://www.ensembl.org/Homo_sapiens/martview 20 676
Kim et al. (11)
supplementary data
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active promoters (hg16, NCBI Build 34) in the human cell
line IMR90 (ATCC). Using the RefSeq indexed results in
supplementary Table 2 from that paper, we added these active
promoter site coordinates to CancerGenes gene data. This
hg16 coordinate data are linked to the UCSC Genome brow-
ser’s LiftOver utility (http://genome.ucsc.edu/cgi-bin/
hgLiftOver), which converts these hg16 coordinates to
coordinates of more recent human genome builds. Experi-
mental data on active promoter regions from other groups,
as they become available, will be added using a similar
process.
COSMIC mutation data from the Sanger Institute
Sanger Institute COSMIC is an ongoing curation effort
sponsored by the Sanger Institute to collect mutation data
from the scientiﬁc literature (6). As of this writing, it includes
data on  3300 distinct mutations in over 1300 genes from
more than 250 000 samples. We downloaded the June 7,
2006 release of COSMIC (v19) (latest release available at
ftp://ftp.sanger.ac.uk/pub/CGP/cosmic), parsed ﬁles for muta-
tion frequencies and tissue distributions on each of the cata-
logued genes for inclusion into the MySQL database.
Literature source gene lists
Through both manual and automated methods, we have
produced four gene lists, which are based upon peer-reviewed
publications that review cancer-related processes. Mitelman
(13) reviewed common chromosome aberrations in cancer.
Hahn and Weinberg (7) and Vogelstein and Kinzler (8)
both review protein and gene pathways important in cancer
development, maintenance and metastasis. Futreal et al. (4)
performed a census of somatic mutation bearing genes related
to cancer. We manually extracted gene symbols from the ﬁrst
three reviews and converted these to Entrez Gene ids.
However, since the gene lists given in Futreal et al. formed
the basis for the Sanger Institute’s Cancer Gene Census
(CGC) resource, we have downloaded the current gene list
and have used that to populate this list in CancerGenes. All
of these literature source lists appear in a multiple-select
drop down menu in the web interface (see below) and may
be unioned or intersected with each other and/or the annota-
tion gene lists (see below). In Table 4 we indicate the number
of genes from these Cancer review sources and compare them
to the annotation gene lists.
Annotation gene lists
We have also derived gene lists from reports, studies and
databases that have not undergone the stringent peer-review
process; we call these ‘annotation’ gene lists and have sepa-
rated these in the CancerGenes web interface (below). As of
this writing, we have loaded three types of annotation gene
lists, including curated cancer-related pathways (from cellma-
p.org), function-related Entrez Gene queries and Sanger CGC
mutation categories (Table 4). Cellmap.org pathways were
curated from the scientiﬁc literature by the Institute of Bioin-
formatics (Bangalore, India) under contract to Memorial
Sloan-Kettering’s Computational Biology Center (cBio) and
are available through http://cancer.cellmap.org. We extracted
protein RefSeq ids from these BioPAX formatted (http://
biopax.org) pathways using custom scripts. We performed
several function-based queries of Entrez Gene that are related
to categories important in cancer, such as to retrieve all
genes containing the tyrosine kinase domain, or oncogenes
(Table 5). Finally, we downloaded the latest mutation data
available from the CGC website (http://www.sanger.ac.uk/
genetics/CGP/Census/) and separated gene lists based on dif-
ferent mutation types (i.e. ampliﬁcation, frameshift mutation,
germ-line mutation, large mutation, missense mutation, non-
sense mutation, splicing mutation and translocation). For all
of these lists, newline-delimited Entrez Gene ids were gener-
ated and subsequently loaded into our MySQL database
(described below).
Table 4. CancerGenes cancer-related literature and annotation lists
List type Description Number of lists Number of genes
Cancer review Peer-reviewed literature sources describing cancer pathways,
recurrent aberrations and mutations
4 400
Cellmap.org Cancer-related, human-curated pathways from Institute of
Bioinformatics (Bangalore, India) under contract to
MSKCC Computational Biology Center
9 578
Entrez query Function-related queries to NCBI’s Entrez Gene resource 6 1691
Sanger CGC Cancer mutation categories from Sanger Institute’s Cancer
Gene Census
7 344
Table 3. Ensembl BioMart query parameters for InterPro protein domain
information
Step Field Settings
1. Dataset Ensembl 39
Homo sapiens genes (NCBI36)
2. Filter Gene: ID List limit EntrezGene ID(s)
3. Output Protein InterPro description
External references EntrezGene ID
Output format Text, tab separated
Table 2. Ensembl BioMart query parameters for gene structure information
Step Field Settings
1. Dataset Ensembl 39
Homo sapiens genes (NCBI36)
2. Filter Gene: ID List limit EntrezGene ID(s)





External references EntrezGene ID
Output format Text, tab separated
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We have stored all CancerGenes data and gene lists in a
MySQL database. We process this data further and then
store the results in one production table which is then used
by the PHP front-end. We indicate relationships between
records in different tables by Entrez Gene ID. Some relation-
ships are one-to-one, and others many-to-one. For example,
one Entrez Gene ID may have several corresponding RefSeq
ids. We provide validated links to outside resources, includ-
ing the Entrez Gene, UCSC Genome browser and iHOP
(Table 6). An overview of the data sources for CancerGenes
are diagrammed in Figure 1.
Web interface
CancerGenes is available on the World Wide Web at http://
cbio.mskcc.org/cancergenes. The CancerGenes web interface
is built in PHP and is running under SuSe Linux. The web
interface consists of a query section, result summary/export
section, and the resultant gene list (Figure 2). The query
section allows choices of sort key (i.e. number of sources,
number of annotations, COSMIC % mutation, gene symbol,
Entrez Gene ID, chromosome, location, number of samples
and number of mutations) and sort order. In addition, users
may optionally select multiple literature source gene lists
and annotation gene lists, as well as upload an arbitrary list
of Entrez Gene ids of interest. Union (OR) and intersection
(AND) set operations are allowed among and between lists.
A gene symbol or Entrez Gene ID can be entered and used
to highlight entries in the list based on characters in the
gene names, gene symbol or aliases (Figure 3). This feature
allows users to quickly ﬁnd particular genes in the resultant
list. Users may choose to display 10 (default), 100 or
1000 tabulated gene data at a time, and may follow links to
previous or next pages.
Users perform a query by clicking on the ‘Go’ button, and
the following is displayed: total number of genes, page
numbers and ‘jump to’ buttons for any highlighted genes,
an export button, buttons to page forward and backward,
and the tabulated results. Users may click on the export
Table 5. NCBI Entrez Gene active human gene queries performed to generate
annotations lists
List name Entrez query
Oncogene ‘oncogene’[All Fields]
Stability ‘stability gene’[All Fields]
Tumor Suppressor ‘tumor suppressor’[All Fields]
Protein Phosphatase (cd00047 OR pfam04387
OR pfam00102 OR smart00404 OR
smart00194 OR pfam01451 OR cd00115 OR
smart00195 OR pfam00782 OR cd00127 OR
pfam06617 OR cd01530) AND ‘homo
sapiens’[ORGN]
Protein kinase ‘protein kinase’[GO] OR cd00192
[Domain Name] OR ‘serine/threonine
kinase’[GO] NOT pseudogene[All Fields]
NOT hypothetical
Tyrosine kinase cd00192[Domain Name]
Table 6. CancerGenes links to other resources
Resource Description Number
of links
Entrez Gene Database of aggregated gene-centric








iHOP Database of concurring gene and
protein names in scientific literature




Genome browser and database of
position-based genome features
maintained by EMBL and Sanger
Institute
20 676
COSMIC Database of somatic mutations in
cancer curated from the scientific
literature maintained by Sanger
Institute
1172
Figure 1. Overview of the data sources for CancerGenes.
Figure 2. Screenshot of the CancerGenes web interface at http://cbio.mskcc.
org/cancergenes using Apple’s Safari web browser.
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sheet, readable by any of the common spreadsheet programs.
RESULTS
We have produced a gene list-centric resource called
CancerGenes that includes a wide variety of gene-centric
data, literature sources and gene lists created by domain
experts. The software provides user functionalities focused
on user interest driven selection and prioritization of target
genes for re-sequencing projects and design of functional
experiments.
We have designed CancerGenes for the following primary
use cases:
(i) Retrieve data on genes of interest by
(a) Uploading a list of Entrez Gene ids
(b) Selecting preloaded gene list
(c) Generate intersection or union of lists
(ii) Sort genes by occurrence in various published sources
(iii) Estimate re-sequencing cost by retrieving the number of
exons
(iv) Find a gene in the list
(v) Download a list of selected genes and associated data
Table 7 demonstrates some of the pair-wise set operations
possible with the preloaded lists, and characterizes the litera-
ture source and annotation lists preloaded into CancerGenes.
DISCUSSION
CancerGenes is a gene list-centric resource, with its intended
niche being cancer-associated gene selection and prioritiza-
tion through aggregation of relevant information, logical
A
B
Figure 3. Query results for ‘erbb2.’ (A) Query box and result summary with ‘jump to’ buttons and (B) subset of a retrieved gene list showing the highlighted gene
ERBB2.
Table 7. Numbers of genes in pair-wise set intersections and unions of







Cancer review 400 69 (7.6%) 165 (8.6%) 338 (83%)
Cellmap.org 909 578 212 (10%)5 3 ( 6.1%)
Entrez query 1926 2057 1691 135 (7.1%)
Sanger CGC 406 869 1900 344
The diagonal cells (yellow) contain the number of genes in each list (given in
the head row and column). The uppermost, left-hand cell (pink) contains the
totalnumberofgenesononeormorelist.Numbersaboveandtotherightofthe
diagonal are the number of genes in a pair-wise set intersection (overlap)
between two lists (one in the top row, the other in the leftmost column).
Numbersbelowandtotheleftofthediagonalarethenumberofgenesresulting
from a pair-wise set union. Percent overlap is given in parentheses, and is the
number of genes in the intersection of two lists divided by the number of genes
in the union of two lists. Most overlaps are 10% or less, with the exception of
the overlap of Cancer review and Sanger CGC, which is 83%.
Nucleic Acids Research, 2007, Vol. 35, Database issue D725operations on lists, selection options and summary presenta-
tion. This is in contrast to the large number of bioinformatics
resources that support gene-centric queries and retrieve
aggregated gene-centric information, or support genome
sequence browsing. In fact, we have retrieved data from a
number of these gene-centric resources (e.g. NCBI Entrez
Gene, Ensembl BioMart, Sanger COSMIC). However, as
CancerGenes’s intended user population deals in gene lists,
rather than individual gene records, we have focused on
gene list-based functionalities, such as union and intersection
set operations, rather than single gene-based queries. In addi-
tion, we have preloaded lists of genes that we anticipate our
target audience will ﬁnd useful, including list provided by
domain experts. In addition to the list-centric operations, as
all active human genes from Entrez Gene are included in
CancerGenes, and as it supports a number of use cases,
projects that requires gene-centric data may also ﬁnd this
resource useful.
Because of our interest in cancer, we have loaded cancer-
focused data and lists into CancerGenes. It is our desire to
support cancer genome sequencing projects, such as the
TGCA with this resource. However, there is no reason why
CancerGenes could not support other re-sequencing projects,
which target other diseases with a genetic component.
Our intent with the four types of preloaded gene lists—
Cancer review, Cellmap.org Pathways, Entrez query and
Sanger CGC—was to cover all genes likely to be related to
cancer through mutation. Table 7 shows the sizes and num-
bers of genes resulting from set intersection (overlap) and
union operations between these four types of preloaded
gene lists. Most relative overlaps between lists (i.e. intersec-
tion size divided by union size) are  10%, with the exception
of the overlap between Cancer review and Sanger CGC,
which is 83%. We are not surprised by these results, because
of our criteria used to generate each list (see Materials and
Methods and Tables 4 and 5).
There are a total of 2274 unique genes in our preloaded
lists, which means annotation coverage of all 39 250 genes in
CancerGenes is 5.8%. If the Sanger CGC list is consi-
dered deﬁnitive in regard to current state of knowledge
about mutated genes in cancer, then 15% (344/2274) of this
5.8% is known to be due to mutation. Conﬁrmation of a
mutation-based association to cancer for the remaining 85%
of genes in our preloaded lists (and  5% of all genes), will
have to await the conclusion of the many cancer genome
sequencing initiatives.
CancerGenes consolidates information from several gene-
centric resources of use to those embarking on gene re-
sequencing efforts large or small. Our focus in developing
this resource has been on simple gene list-centric query
tools and the tabular display of information. The simple
and ﬂexible architecture we have developed for storing and
annotating gene lists will allow us to keep pace with the
currently rapid development of gene lists, sets and signatures,
and provide an up-to-date resource for our users.
FUTURE DEVELOPMENTS
We have planned several developments to make CancerGenes
more useful to cancer genome projects, as well as other
gene re-sequencing initiatives that aim to survey somatic or
germ-line genetic variation of genes. These plans include add-
ing gene-centric data, such as PCR primer and amplicon pre-
dictions, and a re-sequencing ‘difﬁculty’ score (perhaps
based on regional genomic GC-content variations, amplicon
sizes and presence of pseudogenes), We also plan to add pre-
loaded gene lists for genetic diseases other than cancer (e.g.
Kegg pathways), and adding functionalities, such as sequence
retrievals and selected ﬁeld downloads. Finally, we plan to col-
laborate with additional disease domain experts for inclusion
of particular gene lists or particular disease annotations into
the database underlying CancerGenes.
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